Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage KSY1a
- Development stage
- Preclinical
- Lead developer
- Nanyang Technological University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Inhalation, Intravenous
01
Overview
Bacteriophage KSY1a is an investigational, strictly lytic jumbo phage belonging to the *Phikzvirus* genus, with a genome size of approximately 282,489 bp. Maintained within the Singapore Phage Repository, KSY1a is developed for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Pseudomonas aeruginosa* infections, including pneumonia and indwelling medical device-associated infections (such as vascular graft infections). KSY1a targets and binds to the flagella of *P. aeruginosa*. Resistance to KSY1a is associated with mutations in flagellar genes (such as FliE, FliM, and FlgL), which impairs the bacteria's ability to form biofilms and reduces their overall virulence, thereby imposing a significant fitness cost. KSY1a is administered via nebulized inhalation or intravenous infusion, typically in combination with conventional antibiotics to achieve synergistic bactericidal effects and prevent bacterial regrowth.
- Other names
- KSY1a phageKSY-1a phageKSY 1a phagephage KSY1a
02
Targets
Pseudomonas aeruginosa flagellum
Beyond the preview
Go deeper on bacteriophage KSY1a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage KSY1a.